Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Retained Earnings (2022 - 2026)

Immunome filings provide 5 years of Retained Earnings readings, the most recent being -$782.0 million for Q1 2026.

  • On a quarterly basis, Retained Earnings fell 26066566.67% to -$782.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$782.0 million, a 26066566.67% decrease, with the full-year FY2025 number at -$728.2 million, down 41.18% from a year prior.
  • Retained Earnings hit -$782.0 million in Q1 2026 for Immunome, down from -$728.2 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $22000.0 in Q4 2023 to a low of -$782.0 million in Q1 2026.
  • Median Retained Earnings over the past 5 years was -$352.3 million (2024), compared with a mean of -$330.4 million.
  • Biggest five-year swings in Retained Earnings: surged 100.02% in 2023 and later tumbled 26066566.67% in 2026.
  • Immunome's Retained Earnings stood at -$116.0 million in 2022, then soared by 100.02% to $22000.0 in 2023, then crashed by 2344509.09% to -$515.8 million in 2024, then tumbled by 41.18% to -$728.2 million in 2025, then decreased by 7.39% to -$782.0 million in 2026.
  • The last three reported values for Retained Earnings were -$782.0 million (Q1 2026), -$728.2 million (Q4 2025), and -$600.8 million (Q2 2025) per Business Quant data.